Faculty Information - 藤田　俊一 |

（Last updated : 2021-01-21 10:02:16）

藤田　俊一
Department ,

Position

■ Journal

1.	2021/01	Certolizumab pegol-induced immunoglobulin A vasculitis in a patient with rheumatoid arthritis
2.	2020/11/21	A tiger man: a case of muscular sarcoidosis
3.	2020/09/23	Tattoo skin reaction as a skin manifestation of systemic sarcoidosis
4.	2020/07/10	Severe oral stomatitis due to reactivation of herpes simplex virus type 1 in a methotrexate-treated patient with dermatomyositis.
5.	2020/06/10	Effect of Angiotensin II on Bone Erosion and Systemic Bone Loss in Mice with Tumor Necrosis Factor-Mediated Arthritis
6.	2019/10/31	Paraneoplastic Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Should be Treated with Low-dose Prednisolone During Pembrolizumab Therapy
7.	2019/07	Tuberculous fasciitis in a patient with systemic lupus erythematosus.
8.	2019/05	Infection of Helicobacter cinaedi Should be Treated for an Adequate Duration with Combined Antibiotic Therapy: Author's Reply.
9.	2019/03	Japanese Spotted Fever: A Rare Cause of Arthritis
10.	2019/02/22	Tankyrase (PARP5) Inhibition Induces Bone Loss through Accumulation of Its Substrate SH3BP2.
11.	2019/01	Complete resolution of giant cell arteritis after tocilizumab monotherapy determined by positron emission tomography-CT
12.	2018/12	Bacteremia possibly caused by Helicobacter cinaedi and associated with painful erythema in rheumatoid arthritis with malignant lymphoma
13.	2018/10	Bladder carcinoma in situ in a patient with lupus cystitis
14.	2018/03	IgG4-related autoimmune pancreatitis complicated by splenic artery pseudoaneurysm.
15.	2018/03	Treatment of refractory rheumatoid pleural effusion with abatacept.
16.	2018/01	Pharmacological inhibition of tankyrase induces bone loss in mice by increasing osteoclastogenesis.
17.	2015/04	Development of aseptic subcutaneous abscess after tocilizumab therapy in a patient with SAPHO syndrome complicated by amyloid A amyloidosis
18.	2014/07	ACT-Ray study
Display 5 items
Display all(18)

■ Presentation

1.	2020/10/24	Edit Effect of Angiotensin II on Bone Erosion and Systemic Bone Loss in Mice with Tumor Necrosis Factor-Mediated Arthritis
2.	2019/04/17	SH3BP2 gain-of-function mutation ameliorates lupus in B6.MRL-Faslpr mice
3.	2018/04/27	Bone systemic administration of angiotensin II and its type 1 receptor gene deletion exacerbates erosive bone destruction in hTNF-transgenic arthritis mice
4.	2018/04/27	Myostatin inhibition reduces bone loss in an unloading osteoporosis model
5.	2018/04/27	Pharmacological inhibition of tankyrase induces bone loss in mice by increasing osteoclastgenesis
6.	2018/04/27	SH3BP2 gain-of-function mutation alleviates lupus phenotypes in B6.MRL-Faslpr mice
7.	2018/04/26	Functional analysis of the novel G58V mutation in the TNFRSF1A gene identified in a family with TNF receptor-associated periodic syndrome(TRAPS)
8.	2017/11/07	SH3BP2 Gain-of-Function Mutation Ameliorates Lupus in B6.MRL-Faslpr Mice
9.	2017/11/06	Angiotensin II Type I Receptor Deficiency Exacerbates Erosive Bone Destruction ofhTNF-Transgenic Arthritis Mice
10.	2017/11/05	Functional Analysis of the Novel G58V Mutation in the TNFRSF1A Gene Identified in a Family with TNF Receptor-Associated Periodic Syndrome (TRAPS)
11.	2017/11/05	Tankyrase/Wnt Inhibitor Upregulates Osteoclastogenesis and Osteoblastogenesis Via SH3BP2
12.	2017/11/05	The Effect of Myostatin Inhibition on Bone Loss in Murine Osteoporosis Models
13.	2017/04/21	Tankyrase regulates bone mass and osteoclastogenesis
14.	2017/04/20	Angiotensin II exacerbates bone destruction in human TNF-transgenic arthritis mice
15.	2017/04/20	The effect of myostatin inhibition on bone loss in murine osteoporosis models
16.	2016/11/14	Tankyrase Regulates Osteoclastogenesis Via SH3BP2
17.	2016/11/13	Angiotensin II Exacerbates Bone Destruction in TNF-Transgenic Arthritis Mice
18.	2016/04/23	Tankyrase Inhibitor Promotes Osteoclastogenesis by Enhancing SH3BP2 expression
19.	2015/11/16	Tankyrase regulates osteoclastogenesis via SH3BP2 expression
20.	2012/05/09	Biological agents for rheumatoid arthritis (RA) after the short term remission of methotrexate-associated lymphoproliferative disorders (MTX-LPD)
Display 5 items
Display all(20)